Article Text

PDF
Hsulf-1 regulates growth and invasion of pancreatic cancer cells
  1. I Abiatari,
  2. J Kleeff,
  3. J Li,
  4. K Felix,
  5. M W Büchler,
  6. H Friess
  1. Department of General Surgery, University of Heidelberg, Heidelberg, Germany
  1. Correspondence to:
 J Kleeff
 Department of General Surgery, University of Heidelberg, Im Neuenheimer Feld 110, 69120 Heidelberg, Germany;joerg_kleeff{at}med.uni-heidelberg.de

Abstract

Background: Hsulf-1 is a newly identified enzyme with arylsulphatase activity that can regulate the sulphation state of cell-surface heparan sulphate proteoglycans (HSPGs). In vitro overexpression of this enzyme in pancreatic cancer cells decreases responsiveness to fibroblastic growth factor-2, as Hsulf-1 is up regulated in primary pancreatic adenocarcinoma.

Aim: To further analyse the functions of the Hsulf-1 enzyme in vitro and in vivo with respect to growth, invasion and tumorigenicity.

Methods and results: Transfection of Panc-1 pancreatic cancer cells with a full-length Hsulf-1 expression vector resulted in increased invasiveness and adhesiveness. An in vivo xenograft nude mouse tumour model showed a markedly reduced growth potential of Hsulf-1-expressing Panc-1 cells, which correlated with a considerably lower proliferation rate. Hsulf-1-positive nude mouse tumours showed better development of interstitial matrix structures, with increased blood vessel density in these tumours. In an orthotopic model, Hsulf-1-positive tumours exhibited enhanced local invasiveness. In human primary pancreatic cancers there was strong staining for sulphated HSPGs, which was markedly reduced in metastatic tissue samples.

Conclusion: Hsulf-1-mediated desulphation of HSPGs reduces the growth ability of Panc-1 pancreatic cancer cells, but increases the basal invasiveness of these cells, suggesting an important role of this enzyme in pancreatic cancer progression.

  • DMEM, Dulbecco’s modified Eagle’s medium
  • HSPGs, heparan sulphate proteoglycans

Statistics from Altmetric.com

Footnotes

  • Published Online First 7 April 2006

  • Competing interests: None.

  • Ethical approval: The ethics committees of the University of Heidelberg and the University of Bern approved all the studies. Written informed consent was obtained from all patients.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.